Phathom Pharmaceuticals Faces Securities Probe Over Revenue Guidance

The investigation centers on potential securities law violations regarding statements made by Phathom leadership earlier this year. During a February earnings call, CEO Steve Basta touted a revenue target of $320 million to $345 million, citing the company’s GI-focused strategy. This range was reiterated by both Basta and CFO Sanjeev Narula on April 30, 2026. Shortly thereafter, the company revised its fiscal year forecast downward to a range of $310 million to $325 million, falling significantly short of analyst models and management's previous assurances.

Legal representatives at SueWallSt, a division of Levi & Korsinsky LLP, are currently evaluating claims for shareholders who purchased stock during the period the higher guidance was in effect. The firm, a repeat honoree in the ISS Securities Class Action Services Top 50, is reviewing whether these statements constituted misleading information. Investors are encouraged to gather brokerage records documenting purchase dates and transaction costs to determine their eligibility for potential recovery, as the investigation proceeds on a contingency basis with no upfront costs for participants.